Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · STAAR Surgical (STAA)

STAAR Surgical names Warren Foust and Deborah Andrews interim co-CEOs

Neutral Impact 4 of 5 leadership Written later

STAAR Surgical appointed Warren Foust, its President and Chief Operating Officer, and Deborah Andrews, its Chief Financial Officer, as interim co-Chief Executive Officers effective February 1, 2026, after Stephen C. Farrell stepped down as CEO effective January 31, 2026. The Board has started a global search for a permanent CEO, and the filing describes the interim arrangement as a period of transition.

Key points

  • Stephen C. Farrell stepped down as CEO effective January 31, 2026, under a Cooperation Agreement with Broadwood Partners, L.P. dated January 14, 2026.
  • Each interim co-CEO receives restricted stock units with a grant date fair value of $375,000, vesting August 1, 2026.
  • The interim term ends on the earlier of August 1, 2026 or the public announcement of a new CEO; a Search Committee chaired by Lilian Y. Zhou is leading the search.
  • Under a letter agreement with Mr. Foust dated February 1, 2026, additional payments apply if he is not offered the CEO position, including a $250,000 cash recognition and retention award installment in certain cases.

The filing

CompanySTAAR Surgical (STAA)
Form8-K, current report
Filed with the SECFeb 2, 2026, 7:00 AM ET
Accession number0001193125-26-032630

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.